Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | EHA: AML immuno-oncology updates

Lars Bullinger, MD, of Charité University of Medicine, Berlin, Germany, discusses progress in immuno-oncology for the treatment of acute myeloid leukemia (AML). Specifically discussed is the identification of a new checkpoint, CD47, which is expressed on macrophages within the tumor microenvironment as well as compound CAR-T cells and BiTEs presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.